ŠMÍD, Martin, Luděk BEREC, Lenka PŘIBYLOVÁ, Ondřej MÁJEK, Tomáš PAVLÍK, Jiří JARKOVSKÝ, Jakub WEINER, Tamara BARUSOVÁ and Jan TRNKA. Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2. The Journal of Infectious Diseases. Oxford University Press, 2022, vol. 226, No 8, p. 1385-1390. ISSN 0022-1899. Available from: https://dx.doi.org/10.1093/infdis/jiac161.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2
Authors ŠMÍD, Martin (guarantor), Luděk BEREC, Lenka PŘIBYLOVÁ (203 Czech Republic, belonging to the institution), Ondřej MÁJEK (203 Czech Republic, belonging to the institution), Tomáš PAVLÍK (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Jakub WEINER, Tamara BARUSOVÁ and Jan TRNKA.
Edition The Journal of Infectious Diseases, Oxford University Press, 2022, 0022-1899.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30303 Infectious Diseases
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.400
RIV identification code RIV/00216224:14110/22:00126263
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1093/infdis/jiac161
UT WoS 000805341600001
Keywords in English COVID-19; postinfection immunity; vaccine effectiveness; SARS-CoV-2; Omicron variant; hospitalization
Tags 14119612, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 14/3/2023 12:30.
Abstract
Background The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evades immunity conferred by vaccines and previous infections. Methods We used a Cox proportional hazards model and a logistic regression on individual-level population-wide data from the Czech Republic to estimate risks of infection and hospitalization, including severe states. Results A recent (≤2 months) full vaccination reached vaccine effectiveness (VE) of 43% (95% confidence interval [CI], 42%–44%) against infection by Omicron compared to 73% (95% CI, 72%–74%) against Delta. A recent booster increased VE to 56% (95% CI, 55%–56%) against Omicron infection compared to 90% (95% CI, 90%–91%) for Delta. The VE against Omicron hospitalization of a recent full vaccination was 45% (95% 95% CI, 29%–57%), with a recent booster 87% (95% CI, 84%–88%). The VE against the need for oxygen therapy due to Omicron was 57% (95% CI, 32%–72%) for recent vaccination, 90% (95% CI, 87%–92%) for a recent booster. Postinfection protection against Omicron hospitalization declined from 68% (95% CI, 68%–69%) at ≤6 months to 13% (95% CI, 11%–14%) at >6 months after a previous infection. The odds ratios for Omicron relative to Delta were 0.36 (95% CI, .34–.38) for hospitalization, 0.24 (95% CI, .22–.26) for oxygen, and 0.24 (95% CI, .21–.28) for intensive care unit admission. Conclusions Recent vaccination still brings substantial protection against severe outcome for Omicron.
PrintDisplayed: 22/7/2024 15:21